Niraja Suresh
Overview
Explore the profile of Niraja Suresh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
84
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khalil N, Guerra Hernandez C, Farias J, Murray K, Suresh N, Gooch C, et al.
Case Rep Neurol
. 2025 Feb;
17(1):25-30.
PMID: 39981032
We describe maternal and fetal outcomes in a patient who had three successful pregnancies while being treated with eculizumab for AChR+ gMG. This is a follow-up to our previously published...
2.
Allen J, Lin J, Basta I, Dysgaard T, Eggers C, Guptill J, et al.
Lancet Neurol
. 2024 Sep;
23(10):1013-1024.
PMID: 39304241
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system that can lead to severe disability from muscle weakness and sensory disturbances. Around a third...
3.
Fisher K, Diaz S, Gelblum J, Brock C, Suresh N, Towne M
HCA Healthc J Med
. 2024 Sep;
5(4):405-413.
PMID: 39290488
Background: While the reported prevalence of polyneuropathies is 1%-3%, the incidence of hereditary transthyretin amyloidosis in the United States is estimated to be 1 in 100 000 individuals. Polyneuropathies are...
4.
Brandsema J, Ginsberg M, Hoshino H, Mimaki M, Nagata S, Rao V, et al.
Pediatr Neurol
. 2024 May;
156:198-207.
PMID: 38810600
Background: This study evaluated the efficacy and safety of eculizumab, a terminal complement C5 inhibitor, in juvenile generalized myasthenia gravis (gMG). Methods: Adolescents aged 12 to 17 years with refractory...
5.
Zemina K, Pina Y, Malafronte P, Suresh N, Hurst R
SAGE Open Med Case Rep
. 2021 Sep;
9:2050313X211042984.
PMID: 34484793
Toxin-induced leukoencephalopathy is a rare neurological condition that has been previously associated with intracranial radiation, chemotherapy, drugs of abuse, and environmental exposures. Herein, we present a patient with brain-biopsy proven...
6.
Vu T, Anthony N, Alsina R, Harvey B, Schleutker A, Farias J, et al.
Muscle Nerve
. 2021 Jun;
64(3):351-357.
PMID: 34076265
Introduction/aims: Intravenous immunoglobulin (IVIg) is a common therapy for patients with chronic inflammatory demyelinating polyneuropathy (CIDP). IVIg may cause systemic adverse events (AEs); therefore, infusion of subcutaneous immunoglobulin (SCIg) may...
7.
Vu T, Harvey B, Suresh N, Farias J, Gooch C
Case Rep Neurol
. 2021 Mar;
13(1):65-72.
PMID: 33708096
The recombinant humanized monoclonal antibody eculizumab has been shown to be effective and well tolerated in patients with anti-acetylcholine receptor antibody-positive, treatment-refractory generalized myasthenia gravis (gMG). Myasthenia gravis (MG) often...
8.
Fields F, Suresh N, Hiller M, Freed S, Haldar K, Lee S
PLoS One
. 2020 Nov;
15(11):e0234100.
PMID: 33151962
Von Hippel-Lindau disease (VHL) is an autosomal dominant rare disease that causes the formation of angiogenic tumors. When functional, pVHL acts as an E3 ubiquitin ligase that negatively regulates hypoxia...
9.
Pocock K, Suresh N, Suradi Y, Dang S, Harvey B, Cao C, et al.
J Clin Neuromuscul Dis
. 2020 Feb;
21(3):127-134.
PMID: 32073458
Objective: We evaluated the safety and tolerability of higher-dose granulocyte colony-stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis. In addition, rates of disease progression and serum G-CSF levels and...
10.
Suresh N, Haldar K
Curr Opin Pharmacol
. 2018 Aug;
42:46-54.
PMID: 30077118
Artemisinin-based combination therapies (ACTs) have substantially reduced worldwide malaria burden and deaths. But malaria parasites have become resistant to artemisinins. Prior studies suggested two different molecular pathways of artemisinin-resistance. Here...